GuruFocus - On June 27, 2024, William Peters, the Chief Financial Officer, Executive Vice President, and Treasurer of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH), sold 3,596 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 94,103 shares of the company.
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) is a biopharmaceutical company that focuses on the development, manufacturing, and marketing of generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company is involved in the development and sale of insulin active pharmaceutical ingredient products.
Over the past year, William Peters has sold a total of 141,725 shares and has not made any purchases of the company's stock. In the same period, there have been 24 insider sells and no insider buys at Amphastar Pharmaceuticals Inc (NASDAQ:AMPH).
On the day of the sale, shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) were trading at $40.93. This pricing gives the company a market cap of approximately $1.96 billion. The price-earnings ratio of the stock stands at 13.84, which is below both the industry median of 22.18 and the companys historical median.
According to the GF Value, the intrinsic value of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) is estimated at $46.22 per share, suggesting that the stock is modestly undervalued with a price-to-GF-Value ratio of 0.89.
The GF Value is calculated based on historical trading multiples like the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the companys past performance and expected future business outcomes.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.